XFOR vs. VIRI, MIST, ORMP, VXRT, CLYM, ADAG, XBIT, JSPR, BYSI, and CTOR
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Virios Therapeutics (VIRI), Milestone Pharmaceuticals (MIST), Oramed Pharmaceuticals (ORMP), Vaxart (VXRT), Climb Bio (CLYM), Adagene (ADAG), XBiotech (XBIT), Jasper Therapeutics (JSPR), BeyondSpring (BYSI), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs.
X4 Pharmaceuticals (NASDAQ:XFOR) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
X4 Pharmaceuticals has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
In the previous week, X4 Pharmaceuticals had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for X4 Pharmaceuticals and 0 mentions for Virios Therapeutics. X4 Pharmaceuticals' average media sentiment score of 0.64 beat Virios Therapeutics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.
Virios Therapeutics' return on equity of -130.33% beat X4 Pharmaceuticals' return on equity.
72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 2.4% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
X4 Pharmaceuticals presently has a consensus price target of $72.33, indicating a potential upside of 1,931.84%. Virios Therapeutics has a consensus price target of $3.00, indicating a potential downside of 39.15%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Virios Therapeutics.
Virios Therapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals received 77 more outperform votes than Virios Therapeutics when rated by MarketBeat users. Likewise, 68.38% of users gave X4 Pharmaceuticals an outperform vote while only 50.00% of users gave Virios Therapeutics an outperform vote.
Summary
X4 Pharmaceuticals beats Virios Therapeutics on 11 of the 16 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy XFOR Stock Free XFOR Stock Alerts